[Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine].
Gram
L F
LF
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives*; D018967:Risperidone / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine; D010890:Pirenzepine; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors